The main objective of the research group TMI is to discover novel transport mechanisms in the human intestinal tract which could be utilized for oral-systemic delivery of diverse therapeutic modalities (e.g., peptides, oligonucleotides, and antibodies). Studies involve screening of ligands, generating intestinal organoids from murine and human subjects, isolating intestinal cells, and creating a co-culture system. The project’s objectives are to develop a ligand specific for a target cell and establish quantitative assessment methods to monitor macromolecular drug delivery across the intestinal epithelial barrier. Our final goal is to create a novel delivery platform, which can be utilized for the development of a new generation of oral immunotherapies for the benefit of patients.